Full Text View  
  Tabular View  
  Contacts and Locations  
  No Study Results Posted  
  Related Studies  
SuperSTAT Noninvasive Blood Pressure Monitor Evaluation
This study is ongoing, but not recruiting participants.
Sponsored by: GE Healthcare
Information provided by: GE Healthcare
ClinicalTrials.gov Identifier: NCT00603486
  Purpose

The accuracy and/or performance of the GE DINAMAP noninvasive blood pressure (NIBP) monitors may be improved with modifications in software and/or hardware monitoring techniques and/or accessories. When changes are being made to the GE Monitor, testing can be done to evaluate performance of the investigational devices during and/or after product development.


Condition Intervention
Non-Invasive Blood Pressure
Device: GE DINAMAP with SuperSTAT algorithm monitor

U.S. FDA Resources
Study Type: Observational
Study Design: Case-Only, Prospective
Official Title: SuperSTAT Noninvasive Blood Pressure Monitor Evaluation

Further study details as provided by GE Healthcare:

Primary Outcome Measures:
  • Evaluation of one of the GE DINAMAP NIBP Monitor algorithms, SuperSTAT NIBP, in neonatal and/or infant subjects. [ Time Frame: 1 year ] [ Designated as safety issue: No ]

Biospecimen Retention:   None Retained

Biospecimen Description:

Estimated Enrollment: 20
Study Start Date: November 2007
Estimated Study Completion Date: July 2008
Primary Completion Date: May 2008 (Final data collection date for primary outcome measure)
Intervention Details:
    Device: GE DINAMAP with SuperSTAT algorithm monitor
    Apply cuff on a limb, cuff is inflated and deflated, monitor will displays non-invasive blood pressure values (systolic, diastolic, MAP, and pulse rate)
  Eligibility

Ages Eligible for Study:   up to 3 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   Yes
Sampling Method:   Non-Probability Sample
Study Population

Neonates in the NICU and newborn areas and/or infants.

Criteria

Inclusion criteria

  • Signed informed consent
  • Ability to single or dual monitor NIBP, ECG, and/or SpO2, whether or not already being monitored for any or all of these parameters.

Exclusion Criteria

  • Any subject deemed too unstable, at the clinician's discretion, to participate in the study
  • Any subject with a cardiac anomaly that would cause a disparity between aortic pressures and the periphery.
  • Any subject who cannot tolerate, in the opinion of the clinician, multiple blood pressure measurements
  • Known disease state or medical condition that A) compromises circulation to the extremity (ies), B) compromises musculo-skeletal integrity, or C) otherwise contraindicates use of a NIBP cuff and/or SpO2 sensor on an extremity or ECG patches on skin
  • Excessive movement or excitability causing false values or no determinations (SP10 accuracy study only)
  Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT00603486

Locations
United States, Florida
GE Healthcare
Tampa, Florida, United States, 33614
Sponsors and Collaborators
GE Healthcare
Investigators
Principal Investigator: Laura Haubner, MD University of South Florida
  More Information

Responsible Party: University of South Florida ( Laura Haubner, MD )
Study ID Numbers: CS 348
Study First Received: January 7, 2008
Last Updated: July 22, 2008
ClinicalTrials.gov Identifier: NCT00603486  
Health Authority: United States: Institutional Review Board

Keywords provided by GE Healthcare:
Non-invasive Blood Pressure (NIBP)
GE Dinamap
SuperSTAT

ClinicalTrials.gov processed this record on January 14, 2009